RhumbLine Advisers’s CareDx CDNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.94M | Buy |
68,206
+2,706
| +4% | +$58.9K | ﹤0.01% | 1951 |
|
|
2026
Q1 | $1.14M | Sell |
65,500
-3,698
| -5% | -$70K | ﹤0.01% | 2128 |
|
|
2025
Q4 | $1.3M | Sell |
69,198
-12,712
| -16% | -$213K | ﹤0.01% | 2093 |
|
|
2025
Q3 | $1.19M | Sell |
81,910
-2,777
| -3% | -$39.6K | ﹤0.01% | 2153 |
|
|
2025
Q2 | $1.65M | Buy |
84,687
+5,303
| +7% | +$94.2K | ﹤0.01% | 1985 |
|
|
2025
Q1 | $1.41M | Sell |
79,384
-1,817
| -2% | -$39.1K | ﹤0.01% | 2000 |
|
|
2024
Q4 | $1.74M | Buy |
81,201
+1,451
| +2% | +$35.3K | ﹤0.01% | 1963 |
|
|
2024
Q3 | $2.49M | Sell |
79,750
-4,409
| -5% | -$110K | ﹤0.01% | 1787 |
|
|
2024
Q2 | $1.31M | Sell |
84,159
-3,646
| -4% | -$44.1K | ﹤0.01% | 2102 |
|
|
2024
Q1 | $930K | Buy |
87,805
+625
| +0.7% | +$6.25K | ﹤0.01% | 2292 |
|
|
2023
Q4 | $1.05M | Sell |
87,180
-2,124
| -2% | -$17.4K | ﹤0.01% | 2224 |
|
|
2023
Q3 | $625K | Sell |
89,304
-1,352
| -1% | -$12.5K | ﹤0.01% | 2476 |
|
|
2023
Q2 | $771K | Buy |
90,656
+22,240
| +33% | +$185K | ﹤0.01% | 2435 |
|
|
2023
Q1 | $625K | Buy |
68,416
+1,509
| +2% | +$19.3K | ﹤0.01% | 2340 |
|
|
2022
Q4 | $763K | Buy |
66,907
+2,027
| +3% | +$30K | ﹤0.01% | 2270 |
|
|
2022
Q3 | $1.1M | Buy |
64,880
+3,484
| +6% | +$74.8K | ﹤0.01% | 2077 |
|
|
2022
Q2 | $1.32M | Buy |
61,396
+6,266
| +11% | +$174K | ﹤0.01% | 1995 |
|
|
2022
Q1 | $2.04M | Buy |
55,130
+481
| +0.9% | +$18.7K | ﹤0.01% | 1811 |
|
|
2021
Q4 | $2.48M | Sell |
54,649
-622
| -1% | -$32.5K | ﹤0.01% | 1760 |
|
|
2021
Q3 | $3.5M | Buy |
55,271
+1,731
| +3% | +$132K | ﹤0.01% | 1571 |
|
|
2021
Q2 | $4.9M | Sell |
53,540
-2,151
| -4% | -$171K | 0.01% | 1437 |
|
|
2021
Q1 | $3.79M | Sell |
55,691
-5,029
| -8% | -$390K | 0.01% | 1563 |
|
|
2020
Q4 | $4.4M | Buy |
60,720
+2,750
| +5% | +$159K | 0.01% | 1429 |
|
|
2020
Q3 | $2.2M | Sell |
57,970
-8,770
| -13% | -$296K | ﹤0.01% | 1626 |
|
|
2020
Q2 | $2.37M | Buy |
66,740
+9,288
| +16% | +$264K | ﹤0.01% | 1635 |
|
|
2020
Q1 | $1.25M | Buy |
57,452
+374
| +0.7% | +$8.38K | ﹤0.01% | 1778 |
|
|
2019
Q4 | $1.23M | Buy |
57,078
+2,302
| +4% | +$52.8K | ﹤0.01% | 1986 |
|
|
2019
Q3 | $1.24M | Buy |
54,776
+584
| +1% | +$16.2K | ﹤0.01% | 1938 |
|
|
2019
Q2 | $1.95M | Buy |
54,192
+7,848
| +17% | +$251K | ﹤0.01% | 1759 |
|
|
2019
Q1 | $1.46M | Buy |
46,344
+987
| +2% | +$28.8K | ﹤0.01% | 1871 |
|
|
2018
Q4 | $1.14M | Buy |
45,357
+15,752
| +53% | +$405K | ﹤0.01% | 1938 |
|
|
2018
Q3 | $854K | Sell |
29,605
-1,188
| -4% | -$22.2K | ﹤0.01% | 2067 |
|
|
2018
Q2 | $377K | Buy |
+30,793
| New | +$353K | ﹤0.01% | 2435 |
|
Other funds holding CDNA
DM
AIM
GS
RhumbLine Advisers's CDNA Position: Q2 2026 in Review
RhumbLine Advisers increased its CareDx (CDNA) stake by 4.1% in Q2 2026, buying an estimated $58.9K and bringing the position to 68,206 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1951.
RhumbLine Advisers first reported a position in CDNA in Q2 2018 and has held it in 33 quarters since. The position peaked at $4.9M in Q2 2021. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.
- RhumbLine Advisers held 68,206 shares of CareDx worth $1.94M as of Q2 2026.
- RhumbLine Advisers bought 2,706 CareDx shares in Q2 2026, an estimated $58.9K.
- CareDx made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1951 holding.
- RhumbLine Advisers first reported a position in CareDx in Q2 2018 and has held it in 33 quarters since.
- RhumbLine Advisers's CareDx position peaked at $4.9M in Q2 2021.
- 227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.